IP Library › Granted Patent US 11,160,918
Granted Patent B2
US 11,160,918 · App. 16/942,271 · Granted Nov 2, 2021

Medical device packaging and related methods

Inventors: Andrew Cook (Troy, NY); Victor Bradford (Troy, NY)
Assignee: Regeneran Pharmaceuticals, Inc.
A61M5/002B65B69/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,160,918
App. No.
16/942,271
Granted
Nov 2, 2021
Kind
B2
Abstract

According to one aspect of the disclosure, packaging for a sterile syringe having a nominal size of less than 1 mL may include a flexible tray having a cavity for containing the syringe. The cavity may include an opening, one or more sidewalls, and a base. A lip may surround the opening, may extend radially outward from the cavity, and may define a periphery of the tray. A removable cover may have a periphery that is adhered to the lip, and the removable cover may be permeable to a gaseous sterilant, including one or more of vaporized hydrogen peroxide or ethylene oxide. A projection may be associated with the base of the cavity and may extend away from the base of the cavity in a direction opposite to the opening of the cavity.

Claims (18)

1. A packaging comprising:

a tray having an opening, a cavity including three cavity portions, a plurality of sidewalls, and a base;

a sterile syringe contained within the cavity, wherein the sterile syringe is pre-filled with a medicament;

wherein a first cavity portion comprises a plunger of the sterile syringe, a second cavity portion comprises a barrel of the sterile syringe, and a third cavity portion comprises a needle attachment portion of the sterile syringe, wherein the three cavity portions are connected to one another by intermediate narrowed portions,

the narrowed portions including a plurality of geometric features projecting into the narrowed portions to position the sterile syringe away from the plurality of sidewalls, and

wherein the sterile syringe extends through the narrowed portions,

a removable cover sealing the opening, wherein the removable cover is permeable to a gaseous sterilant configured to maintain a sterile barrier, and

a projection associated with the tray at a location in line with a portion of the sterile syringe;

wherein, in a first state, the projection extends away from the sterile syringe in a direction opposite from the opening of the cavity;

wherein the projection is configured to transition from the first state to a second state when subjected to pressure; and

wherein, in the second state, the projection is inverted so that a portion of the projection extends towards the portion of the sterile syringe in line with the projection.

2. The packaging of claim 1 , wherein the projection is located in line with a barrel of the sterile syringe when in the first state.

3. The packaging of claim 1 , wherein the medicament is one of aflibercept, ranibizumab, bevacizumab, conbercept, OPT-302, RTH258 (brolocizumab), a pegylated designed ankyrin repeating protein (DARPin), or RG7716.

4. The packaging of claim 1 , wherein the projection is dome-shaped, and wherein a diameter of the base of the dome-shaped projection is approximately 10 mm to 20 mm.

5. The packaging of claim 1 , wherein the three cavity portions are arranged in series along a longitudinal axis of the tray.

6. The packaging of claim 5 , wherein the second cavity portion is located between the first cavity portion and the third cavity portion.

7. The packaging of claim 1 , wherein the tray is formed from a suitable thermoplastic material, including one or more of polypropylene, polystyrene, polyethylene, polycarbonate, polyvinyl chloride, or polyethylene terephthalate glycol.

8. The packaging of claim 1 , wherein a depth of the projection from an apex of the projection to a base of the projection is approximately 5 mm to 6 mm, and a distance between the base of the projection and a portion of the syringe overlying the projection is approximately 3 mm to 4 mm.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2020
From: COOK, ANDREW; BRADFORD, VICTOR
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 054561/0330 →
Continuity (2)
Provisional Application 62879906 · Jul 29, 2019
Related Publication 20210030945A1 · Feb 4, 2021
Cited By (13)
US 1,116,103 US 1,120,314 US 1,129,277 US 1,129,278 US 12,233,177 US 12,274,865 US 12,318,571 US 12,458,746 US 12,649,031 US 12,691,227 US 12,734,300 US 12,741,098 US 12,746,301